Eliz­a­beth War­ren pro­pos­es us­ing com­pul­so­ry li­cens­ing, an­titrust ac­tions to break bio­phar­ma’s con­trol of drug ...

6 years ago
Bioregnum
Pharma

In rare po­lit­i­cal for­ay, top biotech in­vestors urge Con­gress to re­ject drug pric­ing bill

6 years ago
R&D

Dicer­na scores broad, 'rest of liv­er' deal with No­vo Nordisk, bag­ging $225M in cash to hit some 30 tar­gets with RNAi ...

6 years ago
Deals

Gene ther­a­py wins the in­side track at EMA; PPD files for IPO

6 years ago
News Briefing

Pfiz­er gets biosim­i­lar ap­proved for Hu­mi­ra, set­ting up com­pe­ti­tion — in 2023

6 years ago
R&D

Mer­ck’s $1B cash gam­ble pays off with a sur­pris­ing PhI­II car­dio suc­cess for Bay­er’s heart drug veri­ciguat

6 years ago
R&D

Eye­ing one of the first RNAi ther­a­pies and cho­les­terol block­buster, Med­Co shows de­tailed in­clisir­an da­ta

6 years ago
R&D

Alk­er­mes forges $950M biotech buy­out deal in a bold bet on an ear­ly-stage CNS drug plat­form

6 years ago
R&D

Dutch di­ag­nos­tics play­er Qi­a­gen con­firms buy­out talks fol­low­ing re­port of Ther­mo Fish­er's in­ter­est

6 years ago
Deals

Af­ter a late-stage miss, No­var­tis touts an­oth­er En­tresto analy­sis to con­vince the FDA to ex­pand the block­buster's ...

6 years ago
R&D
Pharma

No­var­tis is ax­ing 150 ear­ly dis­cov­ery jobs as CNI­BR shifts fo­cus to the de­vel­op­ment side of R&D

6 years ago
R&D

Karuna clears PhII hur­dle in schiz­o­phre­nia, takes aim at a piv­otal in block­buster hunt — shares soar

6 years ago
R&D

FTC clears Bris­tol-My­ers’ $74B deal to buy Cel­gene — but Dems sig­nal a po­ten­tial hard shift against Big Phar­ma ...

6 years ago
Pharma

No­var­tis scores its lat­est FDA OK — this time for a new sick­le cell dis­ease drug picked up in a $665M deal

6 years ago
R&D

As­traZeneca gains EU nod for di­a­betes triple; Am­gen and Duke launch re­al-world PC­SK9 ob­ser­va­tion­al study

6 years ago
News Briefing

Five drugs, in­clud­ing two No­var­tis ther­a­pies, win EMA en­dorse­ment

6 years ago
R&D
FDA+

Atom­wise's X-37 spin­out gets $14.5 mil­lion to launch AI dis­cov­ery ef­forts

6 years ago
R&D

Ab­bott Lab­o­ra­to­ries CEO Miles White pass­es ba­ton down to suc­ces­sor; Lon­za CEO Marc Funk hits the ex­it

6 years ago
Peer Review

UCB adds on more pos­i­tive PhI­II da­ta for IL-17A/17F in­hibitor bimek­izum­ab, clear­ing a path to the FDA

6 years ago
R&D

EMA fi­nal­izes clin­i­cal de­vel­op­ment guide­line for new gout treat­ments

6 years ago
FDA+

Roche bags 'break­through' an­ti-fi­bro­sis drug in $1.4B biotech buy­out deal

6 years ago
Deals
R&D

No­var­tis spin­out’s first an­ti-ag­ing PhI­II is a flop, so now they’ll turn to Parkin­son’s chal­lenge as shares ...

6 years ago
R&D

Prepar­ing for new wave of treat­ments, Fu­ji­film drops $55 mil­lion for gene ther­a­py cen­ter

6 years ago
Outsourcing

Af­ter pos­i­tive pan­el vote, Sh­iono­gi an­tibi­ot­ic scores US ap­proval

6 years ago
R&D
First page Previous page 892893894895896897898 Next page Last page
A service from the Financial Times